Profile data is unavailable for this security.
About the company
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
- Revenue in SEK (TTM)45.71m
- Net income in SEK-234.30m
- Incorporated2000
- Employees51.00
- LocationAlligator Bioscience ABSCHEELEVAGEN 2 byggnad 401LUND 223 63SwedenSWE
- Phone+46 465408200
- Fax+46 462864290
- Websitehttps://alligatorbioscience.se/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Saniona AB | 24.88m | -81.81m | 511.14m | 22.00 | -- | 73.71 | -- | 20.55 | -0.9821 | -0.9821 | 0.2822 | 0.0623 | 0.2386 | -- | 6.23 | 1,081,652.00 | -78.47 | -59.16 | -168.78 | -70.15 | -92.01 | -970.05 | -328.83 | -1,483.55 | -- | -3.03 | 0.8668 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
Hamlet BioPharma AB | 0.00 | -41.82m | 562.17m | 7.00 | -- | -- | -- | -- | -0.2756 | -0.2756 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -80.47 | -- | -97.51 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -104.57 | -- | -- | -- |
Cantargia AB | 0.00 | -227.96m | 606.53m | 23.00 | -- | 6.69 | -- | -- | -1.29 | -1.29 | 0.00 | 0.4932 | 0.00 | -- | -- | 0.00 | -98.38 | -55.08 | -129.99 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
Promimic AB | 40.92m | -10.45m | 645.54m | 17.00 | -- | 9.10 | -- | 15.78 | -0.563 | -0.563 | 2.21 | 3.80 | 0.4828 | -3.88 | 3.92 | 2,406,824.00 | -12.33 | -24.89 | -14.16 | -29.25 | 104.60 | 101.23 | -25.54 | -89.47 | 4.51 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
Intellego Technologies AB | 231.25m | 82.86m | 665.40m | 62.00 | 8.34 | 3.08 | 7.35 | 2.88 | 3.03 | 3.03 | 8.50 | 8.20 | 0.8298 | 4.24 | 2.45 | 3,729,807.00 | 29.74 | -- | 37.90 | -- | 68.61 | -- | 35.83 | -- | 1.88 | 8.84 | 0.1532 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
Arcticzymes Technologies ASA | 112.11m | 14.13m | 827.09m | 68.00 | 58.46 | 2.69 | 41.26 | 7.38 | 0.2867 | 0.2867 | 2.27 | 6.24 | 0.3485 | 0.5349 | 6.83 | 1,706,250.00 | 4.39 | 15.58 | 4.63 | 17.22 | 94.39 | 96.69 | 12.60 | 33.23 | 17.25 | -- | 0.0298 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
Alligator Bioscience AB | 45.71m | -234.30m | 997.58m | 51.00 | -- | -- | -- | 21.83 | -0.362 | -0.362 | 0.0696 | -0.0125 | 0.2653 | -- | 9.47 | 788,034.50 | -136.02 | -73.26 | -367.94 | -91.33 | -- | -- | -512.61 | -811.68 | -- | -35.61 | 5.17 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
XSpray Pharma AB (publ) | 0.00 | -214.76m | 1.34bn | 26.00 | -- | 2.46 | -- | -- | -7.05 | -7.05 | 0.00 | 19.79 | 0.00 | -- | -- | 0.00 | -33.11 | -18.38 | -36.76 | -19.26 | -- | -- | -- | -- | 3.50 | -- | 0.0496 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
Diamyd Medical AB | 186.00k | -139.62m | 1.40bn | 25.00 | -- | 7.07 | -- | 7,533.56 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
Nightingale Health Oyj | 49.52m | -198.42m | 1.43bn | 84.00 | -- | 2.27 | -- | 28.85 | -0.29 | -0.29 | 0.0723 | 1.37 | 0.0441 | 2.33 | 3.46 | 51,880.95 | -17.67 | -14.59 | -18.99 | -15.99 | 66.45 | 77.81 | -400.73 | -435.73 | 9.74 | -- | 0.0308 | -- | 4.21 | 16.13 | 3.43 | -- | 8.54 | -- |
Holder | Shares | % Held |
---|---|---|
Handelsbanken Fonder ABas of 31 Jul 2024 | 13.94m | 1.84% |
E. �hman J :or Fonder ABas of 31 Dec 2023 | 6.53m | 0.86% |
FCG Fonder ABas of 31 Dec 2023 | 1.70m | 0.22% |
SEB Investment Management ABas of 28 Jun 2024 | 1.62m | 0.21% |
Storebrand Asset Management ASas of 30 Jun 2024 | 532.51k | 0.07% |
Skandia Investment Management ABas of 31 May 2024 | 95.54k | 0.01% |
Aramea Asset Management AGas of 30 Jun 2022 | 0.00 | 0.00% |